Treatment of epithelial cysts by intracystic injection of antineoplastic particles

US11737972B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11737972-B2
Application numberUS-202218046002-A
CountryUS
Kind codeB2
Filing dateOct 12, 2022
Priority dateJun 9, 2017
Publication dateAug 29, 2023
Grant dateAug 29, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for treating an epithelial cyst, the method comprising injecting a composition comprising an effective amount of paclitaxel particles and an aqueous liquid carrier directly into the epithelial cyst, thereby treating the epithelial cyst, wherein the paclitaxel particles comprise at least 95% be by weight of paclitaxel, wherein the paclitaxel particles have a specific surface area (SSA) of at least 18 m 2 /g, wherein the paclitaxel particles have a mean particle size (number) of from 0.1 microns to 5 microns, wherein the composition comprises a suspension of the paclitaxel particles dispersed in the carrier, and wherein the composition does not contain ethanol. 2. The method of claim 1 , wherein the aqueous liquid carrier comprises 0.9% saline solution. 3. The method of claim 1 , wherein the aqueous liquid carrier comprises a surfactant. 4. The method of claim 3 , wherein the surfactant is a polysorbate. 5. The method of claim 4 , wherein the polysorbate is polysorbate 80 , and wherein the polysorbate 80 is present in the aqueous carrier at a concentration of between about 0.01% v/v and about 1% v/v. 6. The method of claim 1 , wherein the composition further comprises a diluent, wherein the aqueous liquid carrier and the diluent form a mixture, and wherein the composition is a suspension of the paclitaxel particles dispersed in the aqueous liquid carrier/diluent mixture. 7. The method of claim 6 , wherein the diluent comprises 0.9% saline solution. 8. The method of claim 1 , wherein the paclitaxel particles have a bulk density (not tapped) of 0.05 g/cm 3 to 0.15 g/cm 3 . 9. The method of claim 1 , wherein the concentration of the paclitaxel particles in the composition is between about 6 mg/mL and about 15 mg/mL. 10. The method of claim 1 , wherein the paclitaxel particles have a mean particle size (number) of from 0.1 microns to 1.5 microns. 11. The method of claim 1 , wherein the paclitaxel particles are crystalline particles. 12. The method of claim 1 , wherein the composition and paclitaxel particles exclude albumin. 13. The method of claim 1 , wherein cyst fluid is withdrawn from the epithelial cyst prior to injecting the composition. 14. The method of claim 13 , wherein the volume of the composition injected into the epithelial cyst is equal to the volume of cyst fluid removed from the epithelial cyst. 15. The method of claim 1 , wherein the epithelial cyst is a pancreatic cyst. 16. The method of claim 15 , wherein the pancreatic cyst is a mucinous pancreatic cyst. 17. The method of claim 1 , wherein the injecting of the composition is conducted by endoscopic ultrasound-guided fine needle injection (EUS-FNI). 18. The method of claim 1 , wherein the epithelial cyst is reduced in volume/size, is eliminated, or is ablated after injection of the composition, and/or wherein pain associated with the epithelial cyst is reduced.

Assignees

Inventors

Classifications

  • A61K9/0019Primary

    Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

  • for locating instruments · CPC title

  • in body cavities or body tracts, e.g. by using catheters · CPC title

  • A61K9/10Primary

    Dispersions; Emulsions · CPC title

  • Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11737972B2 cover?
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Who is the assignee on this patent?
Crititech Inc
What technology area does this patent fall under?
Primary CPC classification A61K9/0019. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).